Search - tctmd.com

Displaying 161 - 180 of 224

Sort: Relevancy | Date

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Daily News

The Higher the LDL, the Bigger the Mortality Benefit of Intensive Therapy: Meta-analysis

Michael O'Riordan

April 20, 2018

News Daily News

Pills or Even Tea More Palatable Than Exercise for the Treatment of Hypertension, US Adults Say

Michael O'Riordan

April 09, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2018

Shelley Wood

April 02, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Shelley Wood

March 10, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy

Yael L. Maxwell

January 29, 2018

News Daily News

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Yael L. Maxwell

January 24, 2018

News Daily News

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Michael O'Riordan

January 09, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Daily News

Genetic Study Hints at Role of Lipids in AAA Risk

Michael O'Riordan

November 30, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Daily News

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Yael L. Maxwell

October 30, 2017

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Yael L. Maxwell

September 06, 2017

Advertisement

Alirocumab Price Slashed in Deal With Express Scripts

The Higher the LDL, the Bigger the Mortality Benefit of Intensive Therapy: Meta-analysis

Pills or Even Tea More Palatable Than Exercise for the Treatment of Hypertension, US Adults Say

TCTMD’s Top 10 Most Popular Stories for March 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Genetic Study Hints at Role of Lipids in AAA Risk

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content